11:55 AM EST - BioVaxys Technology Corp. : Announced the results of a clinical study conducted by ProCare Health Iberia, its EU partner for marketing its gynecological cancer and viral vaccines, which demonstrated the efficacy of Papilocare® in preventing and treating lesions caused by HPV. BioVaxys has right of refusal for US marketing of Papilocare®, the world's first and only product to prevent and treat HPV-dependent cervical lesions. BioVaxys Technology Corp.
shares C.BIOV are trading unchanged at $0.40.
